PMID-15578997 – Ziconotide Neuronal Calcium Channel Blocker Review
Miljanich GP. "Ziconotide: neuronal calcium channel blocker for treating severe chronic pain," Curr Med Chem, 2004;11(23):3029-3040.
Quick Reference
| Property | Value |
|---|---|
| PMID | 15578997 |
| DOI | 10.2174/0929867043363884 |
| Year | 2004 |
| Journal | Current Medicinal Chemistry |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Ziconotide |
Key Findings
- Ziconotide (SNX-111, Prialt) is the synthetic form of omega-conotoxin MVIIA, a 25-amino acid peptide from the venom of cone snail Conus magus
- Selectively and reversibly blocks N-type voltage-gated calcium channels (CaV2.2) in the dorsal horn of the spinal cord
- N-type calcium channels are critical for neurotransmitter release from primary afferent nociceptors — blocking them prevents substance P, glutamate, and CGRP release
- Unlike opioids, ziconotide does not produce tolerance, physical dependence, respiratory depression, or addiction
- Requires intrathecal administration via implanted pump due to inability to cross the blood-brain barrier from systemic circulation
- Contains three disulfide bonds (Cys1-Cys16, Cys8-Cys20, Cys15-Cys25) that stabilize the inhibitor cystine knot (ICK) structural motif
- The review covers the full development from venom discovery through FDA approval
Study Design
Comprehensive narrative review covering the pharmacology, mechanism of action, clinical development, and therapeutic application of ziconotide. Covers structure-activity relationships, selectivity for N-type vs other calcium channel subtypes, and clinical trial results.
Limitations
- Review article; no new primary data
- Published concurrent with FDA approval; limited long-term clinical experience
- Focus on mechanism rather than clinical outcomes
Clinical Relevance
This review provides the definitive mechanistic overview of ziconotide at the time of its FDA approval. It establishes ziconotide as the first-in-class non-opioid intrathecal analgesic peptide and explains why venom-derived peptides represent a productive source of novel therapeutics. The non-opioid mechanism is especially relevant in the context of the opioid crisis, as ziconotide offers severe pain management without addiction risk. For the vault, this note bridges the basic science of calcium channel pharmacology to clinical pain management.
Related
#research #narrative-review #evidence-level-V #ziconotide #pain